Evidence Weighed for Suicide/Self-Harm With Obesity Drugs
As the EU looks into cases of suicidal thoughts and self-harm associated with the GLP-1 agonists semaglutide, and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents.
Medscape Medical News
source https://www.medscape.com/viewarticle/994266?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/994266?src=rss
Comments
Post a Comment